malaria

A leading scientist on the mechanisms of action of antimalarial medications, the University of North Carolina professor made contributions to research and mentoring all around the world.

A paper published in The Lancet reported that hospitalized COVID-19 patients taking the drug had a higher risk of death, although some researchers have raised questions about the data.

Engineered Plasmodium parasites form the basis of two experimental malaria vaccines that showed safety and encouraging immune responses in clinical trials.

Two studies show that Plasmodium—the genus of protozoans that cause malaria—have an internal sense of time that synchronizes with their host’s circadian rhythms and allows the parasites to collectively attack blood cells.

The report by Didier Raoult and colleagues that examined the use of the anti-malarial drug in a small number of COVID-19 patients receives criticism from the very society that published it.

President Donald Trump has touted the drug as a treatment but scientists still don’t know for sure that it is effective in patients. A number of clinical trials aim to find out.

The study, conducted in Malawi, Kenya, and Ghana, did not obtain informed consent from each parent whose child participated, but rather considered consent “implied” because of the particular experimental design.

While neutrophil extracellular traps help guard the body from infection, they also can contribute to a range of diseases.

The World Health Organization and its partners will test the public health effect of immunization in parts of Malawi, Ghana, and Kenya.

Researchers can now track the expansion of a resistance mechanism that allows the malaria vector Anopholes funestus to detoxify a key insecticide used on bed nets.

The Duke University professor studies the parasite to find a way to thwart infection before it takes hold.

The parasite that causes malaria has evolved to evade many of the drugs that researchers have developed to fight the tropical disease.

Plasmodium falciparum has shown an ability to evade everything we throw at it, most recently artemisinin-based combination therapies, today’s front-line treatment.

The large-scale experiments aim to test how the technology would fare in the wild, if deployed to knock down populations of the pests.

Numerous studies link habitat destruction to malaria and other vector-borne diseases, but the relationship isn’t always clear.

United Nations members agree to some restrictions on the technology, but not a total suspension of its use.

No females were produced after eight generations, causing the population to collapse.

The physiological changes that can occur in the retinas of patients with cerebral malaria may provide a useful approach to diagnosis.

Researchers used the genome sequence of Artemisia annua to boost the plant’s production of artemisinin.

The parasite changes people’s scent, primarily due to an increase in aldehydes.